

# MarÃ-a Teresa Arias-Loste

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1851648/publications.pdf>

Version: 2024-02-01

35  
papers

1,886  
citations

643344

15  
h-index

388640

36  
g-index

36  
all docs

36  
docs citations

36  
times ranked

3301  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of antinuclear antibodies in inflammatory bowel disease and seroconversion after biological therapy. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210778.	1.4	1
2	Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets. <i>Biomedicines</i> , 2022, 10, 46.	1.4	10
3	Elevated risk of liver steatosis in first-episode psychosis patients: Results from a 3-year prospective study. <i>Schizophrenia Research</i> , 2022, 246, 30-38.	1.1	3
4	Innate and Adaptive Immunity Alterations in Metabolic Associated Fatty Liver Disease and Its Implication in COVID-19 Severity. <i>Frontiers in Immunology</i> , 2021, 12, 651728.	2.2	6
5	Successful Direct Acting Antiviral Therapy in Chronic Hepatitis C Normalizes IFN $\gamma$ and IL2 Production in T Cells Together with TLR8 Expression and Functionality in Peripheral Blood Mononuclear Cells. <i>Viruses</i> , 2021, 13, 635.	1.5	2
6	High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort. <i>United European Gastroenterology Journal</i> , 2021, 9, 892-902.	1.6	12
7	Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. <i>EBioMedicine</i> , 2021, 70, 103521.	2.7	11
8	Efficacy and safety of endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy in obese subjects with Non-Alcoholic SteatoHepatitis (NASH): study protocol for a randomized controlled trial (TESLA-NASH study). <i>Trials</i> , 2021, 22, 756.	0.7	15
9	Bacterial antigen translocation and age as BMI-independent contributing factors on systemic inflammation in NAFLD patients. <i>Liver International</i> , 2020, 40, 2182-2193.	1.9	14
10	Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease. <i>PLoS ONE</i> , 2020, 15, e0243590.	1.1	3
11	Management of haemostatic alterations and associated disorders in cirrhosis in Spain: A national survey. <i>Digestive and Liver Disease</i> , 2019, 51, 95-103.	0.4	12
12	Changes in Circulating Lysyl Oxidase-Like-2 (LOXL2) Levels, HOMA, and Fibrosis after Sustained Virological Response by Direct Antiviral Therapy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1242.	1.0	5
13	MicroRNA Profile of HCV Spontaneous Clarified Individuals, Denotes Previous HCV Infection. <i>Journal of Clinical Medicine</i> , 2019, 8, 849.	1.0	11
14	Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 95, 109677.	2.5	20
15	LOXL2 "A New Target in Antifibrogenic Therapy?". <i>International Journal of Molecular Sciences</i> , 2019, 20, 1634.	1.8	50
16	Porto-Sinusoidal Vascular Disease Associated to Oxaliplatin: An Entity to Think about It. <i>Cells</i> , 2019, 8, 1506.	1.8	18
17	Data regarding the effect of cannabis consumption on liver function in the prospective PAFIP cohort of first episode psychosis. <i>Data in Brief</i> , 2019, 27, 104415.	0.5	3
18	A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR. <i>Journal of Hepatology</i> , 2019, 70, 494-500.	1.8	67

#	ARTICLE	IF	CITATIONS
19	Enfermedad hepática por alcohol. Guías de práctica clínica. Documento de consenso auspiciado por la AEEH. Gastroenterología Y Hepatología, 2019, 42, 657-676.	0.2	12
20	An altered fecal microbiota profile in patients with non-alcoholic fatty liver disease (NAFLD) associated with obesity. Revista Espanola De Enfermedades Digestivas, 2019, 111, 275-282.	0.1	41
21	Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica. Gastroenterología Y Hepatología, 2018, 41, 328-349.	0.2	71
22	Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR. Oncotarget, 2018, 9, 30869-30882.	0.8	9
23	Metabolic effects of reduced growth hormone action in fatty liver disease. Hepatology International, 2018, 12, 474-481.	1.9	29
24	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. Journal of Hepatology, 2018, 69, 896-904.	1.8	1,157
25	Impact of an acute hemodynamic response-guided protocol for primary prophylaxis of variceal bleeding. World Journal of Clinical Cases, 2018, 6, 611-623.	0.3	3
26	A morphological method for ammonia detection in liver. PLoS ONE, 2017, 12, e0173914.	1.1	28
27	Increased Expression Profile and Functionality of TLR6 in Peripheral Blood Mononuclear Cells and Hepatocytes of Morbidly Obese Patients with Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2016, 17, 1878.	1.8	28
28	Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study. Psychopharmacology, 2016, 233, 3947-3952.	1.5	40
29	Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease. Scientific Reports, 2016, 6, 31421.	1.6	33
30	The Need for Biomarkers in Diagnosis and Prognosis of Drug-Induced Liver Disease: Does Metabolomics Have Any Role?. BioMed Research International, 2015, 2015, 1-8.	0.9	29
31	The Crosstalk between Hypoxia and Innate Immunity in the Development of Obesity-Related Nonalcoholic Fatty Liver Disease. BioMed Research International, 2015, 2015, 1-8.	0.9	15
32	Plasma betatrophin levels in patients with liver cirrhosis. World Journal of Gastroenterology, 2015, 21, 10662.	1.4	17
33	Binge drinking: Burden of liver disease and beyond. World Journal of Hepatology, 2015, 7, 2703.	0.8	46
34	Irisin, a Link among Fatty Liver Disease, Physical Inactivity and Insulin Resistance. International Journal of Molecular Sciences, 2014, 15, 23163-23178.	1.8	61
35	Epidemiology of intrafamilial inflammatory bowel disease throughout Europe. Annals of Gastroenterology, 2012, 25, 188-192.	0.4	3